Xeris Biopharma CEO accelerates Recorlev outlook, now sees nearly $1B annual sales 3–4 years earlier
supporting higher 2030 revenue view
- CEO now expects lead drug Recorlev to approach nearly $1 billion in annual sales three to four years earlier.
- Raised 2030 total revenue outlook to more than $1 billion.
- Raised 2026 revenue outlook range to $395–$405 million from prior guidance.
- Q3 EPS was $0.06 versus $0.02 expected, outperforming analyst consensus.
- Q3 2026 revenue totaled $107.2M, up 45% YoY and above forecasts, described as rising 44% to $107M.
- Q3 2026 results included net income of $11.3M for the quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.